IMMUNOLOGIC ASPECTS OF PHAGE THERAPY OF INFECTIONS RELATED TO MEDICAL CARE IN NEUROREANIMATION

Cover Page


Cite item

Full Text

Abstract

Aim. Evaluate the effect of anti-phage humoral immune response on effectiveness of phage therapy of infections related to medical care (IRMC). Materials and methods. 42 patients on extended mechanical ventilation (MV) in neuroreanimation, 1 time in 2014, 4 times in 2015 and 1 time in 2016 had received bacteriophage cocktail per os - 20 ml including 6 patients - additionally 3-5 times. Effectiveness of phage therapy was evaluated by seeding of IRMC strains from samples of endotracheal aspirate, blood, urine and feces of patients before and after treatment. Results. 87.5% of samples from the patients initially had gram-negative pathogens (Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa). Effective sanation for the first episodes of phage therapy was confirmed in 54 - 62.5% of cases. Pharmacokinetic studies have indicated a systemic mechanism of action for enteral forms of bacteriophages. Repeated courses of phage therapy did not result in significant eradication of pathogens. Antiphage immunity after a single administration of the cocktail of bacteriophages with a certain strain composition was detected using ELISA by the presence of specific IgG titers in a range from 1/16 to 1/4096 (in patients not receiving the cocktail antibodies were not detected). Conclusion. Reduction of sanation effect of bacteriophage could be due to formation of anti-phage antibodies after a repeated course in the same patient. Changes of strain composition of phage cocktail of bacteriophages is necessary to preserve results of phage therapy.

About the authors

S. S. Bochkareva

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. V. Aleshkin

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

O. N. Ershova

Burdenko Research Institute of Neurosurgery

Email: noemail@neicon.ru
Russian Federation

L. I. Novikova

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

S. S. Afanasiev

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

I. A. Kiseleva

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

E. R. Zulkarneev

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

E. O. Rubalsky

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

O. Yu. Borisova

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

A. V. Karaulov

Sechenov First Moscow State Medical University

Email: noemail@neicon.ru
Russian Federation

References

  1. Алешкин А.В., Светоч Э.А., Воложанцев Н.В. и др. Инновационные направления использования бактериофагов в сфере санитарно-эпидемиологического благополучия, населения Российской Федерации. Бактериология. 2016, 1 (1): 22-31.
  2. Борисова О.Ю., Рубальский Е.О., Алешкин А.В. и др. Применение молекулярногенетических технологий для индикации фагов в крови пациентов с инфекциями, связанными с оказанием медицинской помощи. В: Бактериофаги: теоретические и практические аспекты применения в медицине, ветеринарии и пищевой промышленности. 2016, с. 60-61.
  3. Иммунологические методы. Подред. Г.Фримеля. М, Медицина, 1987.
  4. Руководство по проведению доклинических исследований лекарственных средств (иммунобиологические лекарственные препараты). Часть 2. Под ред. А.Н.Миронова. М., Гриф и К, 2013.
  5. AdamsMH. Methods ofstudy of bacterial viruses./я: Bacteriophages. New York, Interscience, 1959b: p. 443-522.
  6. Aleshkin A., Ershova O., Volozhantsev N. et al. Phagebiotics in treatment and prophylaxis of healthcare-associated infections. In: Bacteriophages: An overview and synthesis of a reemerging field. Ed. Harrington D. New York, Nova Science Publishers Inc., 2016, ISBN: 978-1-63485-455-9, p. 105-122.
  7. Aleshkin A.V., Ershova O.N., Volozhantsev N.V. et al. Phagebiotics in treatment and prophylaxis of healthcare-associated infections. Phagebiotics in treatment and prophylaxis of healthcare-associated infections. Bacteriophage. 2016, 6: el251379.
  8. D^browska K., Miernikiewicza P, Piotrowicza A. et al. Immunogenicity studies of proteins forming the t4 phage head surface. J. Virol. 2014, 88 (21): 12551-12557.
  9. Lusiak-Szelachowska M., Zaczek M., Weber-Dabrowska B. et al. Phage neutralization by sera of patients receiving phage therapy. Viral. Immunol. 2014, 27 (6): 295-304. doi: 10.1089/ vim.2013.0128.
  10. Zaczek M., Lusiak-Szelachowska M., Jonczyk-Matysiak E. et al. Antibody production in response to staphylococcal ms-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 2016, 7: 1681.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bochkareva S.S., Aleshkin A.V., Ershova O.N., Novikova L.I., Afanasiev S.S., Kiseleva I.A., Zulkarneev E.R., Rubalsky E.O., Borisova O.Y., Karaulov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies